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The last decade has brought significant advances in our understanding of antifungal immunity, which offer
hope for the development of novel immunotherapeutics. In this commentary, we provide a snapshot of the
protective innate and adaptive components of antifungal immunity and highlight several recent topics of
interest, placing in context the three associated reviews in this issue of Cell Host & Microbe.Introduction
Of all the pathogens of man, fungi are the
least well studied and understood. The
reasons for this are largely historical;
healthy people rarely get life-threatening
fungal infections, and although many
suffer from superficial fungal infections
of the skin and mucosa, these infections
are often treatable with current antifungal
agents. However, alterations in immune
status or breaching of physical barriers
can render individuals susceptible to life-
threatening invasive fungal diseases,
and the incidence of these types of infec-
tions has increased substantially in the
last few decades due to the HIV/AIDS
pandemic and modern immunosuppres-
sive and invasive medical interventions.
Moreover, invasive fungal diseases are
difficult to diagnose and treat and fre-
quently have mortality rates exceeding
30% to 50%, despite the introduction of
novel classes of antifungals (azoles and
echinocandins) in clinical practice. It was
recently estimated that more people die
annually from invasive fungal diseases
than from tuberculosis (our unpublished
data), and the prognosis for patients with
invasive fungal infections has remained
nearly unchanged in the last two decades.
This fact, in combination with the central
role played by a deficient host defense in
the pathogenesis of fungal infections,
has led to the concept that adjunctive
immunotherapeutic approaches should
be developed to improve the outcome of
the disease. To achieve this goal, we
need to understand the underlying mech-
anisms of protective antifungal immunity,422 Cell Host & Microbe 11, May 17, 2012 ª2and excitingly, this is one area where
there have been significant recent ad-
vances. Here we introduce the major
fungal pathogens that are associated
with human disease and highlight some
of the recent advances in our under-
standing of antifungal immunity.
The Pathogens
Only a few of the million or so known
fungal species are truly pathogenic and
capable of causing life-threatening infec-
tions in healthy individuals. The incidence
of these diseases, such as histoplasmosis
or coccidioidomycosis, is relatively low. In
contrast, the majority of lethal invasive
infections in immunocompromised hosts
are opportunistic infections caused by
normally commensal or saprophytic fungi,
primarily species of Candida, Crypto-
coccus, Aspergillus, and Pneumocystis.
In patients with AIDS, infections with
Pneumocystis jirovecii and Cryptococcus
neoformans (and the closely related
C. gatti, sometimes also found to cause
infection in healthy individuals) are the
most frequent cause of fungal-related
deaths, although non-life-threatening mu-
cosal infections with Candida are also
very common. Similarly, Pneumocystis,
which causes life-threatening respiratory
tract infections, and Cryptococcus, which
preferentially targets the central nervous
system, can also infect other immunosup-
pressed individuals, including transplant
patients. Recent estimates suggest that
there are 620,000 deaths per year in
AIDS patients resulting from cryptococcal
meningitis (Park et al., 2009), making012 Elsevier Inc.Cryptococcus themost lethal fungal path-
ogen of man.
Noninvasive infections of the oral and
genital mucosa are the most common
form of infection with Candida spp.,
but these microorganisms are also re-
sponsible for substantial numbers of inva-
sive systemic and bloodstream infec-
tions in hospital settings, particularly in
severely immunocompromised patients
and patients undergoing invasive clinical
procedures. In fact, Candida species,
particularlyC. albicans, are now the fourth
most common cause of nosocomial
bloodstream infections and the second
leading cause of infectious-related death
in extremely premature infants (Benjamin
et al., 2010; Pfaller and Diekema,
2007). Species of Aspergillus, primarily
A. fumigatus and A. flavus, cause signifi-
cant numbers of invasive fungal infections
in immunocompromised individuals and
are one of the most feared fungal dis-
eases, as they are very difficult to treat
and have the highest rates of mortality. In-
dividuals at risk include solid organ trans-
plant recipients, neutropenic patients
on strongly immunosuppressive thera-
pies, or patients with defects in neu-
trophil function such as chronic gran-
ulomatous disease (CGD). Aspergillus
also causes chronic pulmonary asper-
gillosis, a destructive disease compli-
cating other pulmonary illnesses such as
COPD, and allergic diseases, such as
allergic bronchopulmonary aspergillosis.
Several other species of fungi can also
cause life-threatening infections, includ-
ing Histoplasma, Blastomyces, Rhizopus,
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incidence of each of these infections is
less than those of the four species dis-
cussed above (our unpublished data).
Antifungal Immunity
Fungi have contributed significantly to our
understanding ofmammalian immunology
for well over 100 years (Brown, 2010), yet
major advances in our understanding of
the mechanisms underlying protective
antifungal immunity have occurred only
relatively recently. Keeping with the topic
of the reviews in this issue in this issue of
Cell Host & Microbe, in this commentary
we focus on pattern recognition receptors
(PRRs), dendritic cells (DCs), Th17 immu-
nity, and antibody responses, as these
areas have provided substantial new
insights and offer the potential for the
development of novel immunotherapeutic
approaches. We also aim to provide a
snapshot of the central innate and adap-
tive components of protective antifungal
immunity and to place in context the three
associated reviews.
Innate Immunity: PRRs and DCs
Innate and adaptive immunity to fungal
infections is critically dependent on
phagocytic cells, and loss of these cells
leaves individuals extremely vulnerable to
infection. Neutropenia, for example, pre-
disposes patients to life-threatening infec-
tions with several invasive fungal species
(discussed above), while defects in neu-
trophil mobilization (due to defects in
IL-17 function, for example) result in an
increased predisposition to fungal in-
fections at the mucosa. Phagocytes pos-
sess several oxidative and nonoxidative
effector mechanisms, which are used
synergistically to kill fungi, and defects in
thesemechanisms are also significant risk
factors. Patients with inherited defects in
their phagocyte NADPH oxidase, for
example, develop CGD as they are unable
to induce a respiratory burst and are pre-
disposed to several life-threatening in-
fections, including invasive aspergillosis
(specially with A. nidulans). Importantly,
the antifungal activities of phagocytes are
strongly influenced by the state of cellular
activation,whichcanbeboth substantially
enhanced (by IFN-g, for example) or sup-
pressed (by IL-10 or steroids, for example)
by soluble mediators.
Many of the antimicrobial functions
of phagocytes are triggered following
pathogen recognition by PRRs, and thediscovery of these receptors, particularly
the Toll-like receptors (TLR), was a signifi-
cant advance. Intriguingly, although being
originally discovered in relation to anti-
fungal immunity in fruit flies, the exact
role of individual TLRs in antifungal immu-
nity in mammals is less clear. Indeed,
there is contradictory evidence for the
role of these PRRs for many fungal infec-
tions in experimental mouse models, and
although polymorphisms in TLRs have
been linked to susceptibility in humans,
patients lacking essential downstream
signaling components, such as MyD88,
do not show obvious defects in antifungal
immunity (von Bernuth et al., 2008).
However, the TLRs collaborate with other
PRRs, and while perhaps not essential in
otherwise immunocompetent individuals,
they do play critical roles in modulating
the inflammatory and adaptive responses
to fungal pathogens in the context of
immunosuppression (Netea et al., 2008).
In contrast to the TLR, there is compel-
ling evidence that other classes of PRR,
particularly the C-type lectins (CLR) and
NOD-like receptors (NLRs), play funda-
mental roles in protective antifungal im-
munity. CLRs such as DC-SIGN, the
macrophagemannose receptor, Dectin-1,
Dectin-2, andMincle are involved in fungal
tethering and uptake by phagocytes,
induction of antifungal effector mecha-
nisms, and theproductionof solublemedi-
ators, including inflammatory lipids, cyto-
kines, and chemokines. Importantly, like
the TLRs, these receptors are capable of
directingandmodulating thedevelopment
of adaptive immunity. Studies of the
underlying mechanisms utilized by these
receptors have also revealed novel sig-
naling components, including the Syk/
CARD9 pathway that is utilized by Dec-
tin-1, Dectin-2, and Mincle. Importantly,
polymorphisms or mutations in the CLRs
or their intracellular signaling components
have been linked to susceptibility to
fungal infections in both mouse models
and in humans (Netea and van der Meer,
2011). Of the NLRs, both the NLRP3 and
NLRC4 have been found to play an essen-
tial role in antifungal immunity. These
NLRs are components of inflammasomes,
cytoplasmicmultimeric proteolytic protein
complexes that are involved in the pro-
cessing and activation of IL-1b and IL-18.
How these inflammasomes are actually
induced by fungi is still unclear. More
recently a noncanonical inflammasomeCell Host & Microbeinvolving caspase-8 has also been impli-
cated, but here activation was shown to
be mediated by Dectin-1 (Gringhuis
et al., 2012). The roles and function of all
these PRRs are discussed further in the
associated reviews by Herna´ndez-Santos
and Gaffen (Herna´ndez-Santos and Gaf-
fen, 2012) and by Roy and Klein (Roy and
Klein, 2012) in this issue.
Equally important to the discovery of
PRRs was the finding that phagocytes,
particularly DCs, mediate the induction
and modulation of adaptive immunity.
The unique ability of DCs to present
antigen to naive T cells and drive the
development of adaptive immunity has
prompted substantial interest in identi-
fying and characterizing the function of
DC subsets. In mice (and humans),
several types of DC have been identified,
including plasmacytoid DCs, resident
DCs, and migratory DCs, the latter con-
sisting of several subsets that are found
in different tissues, such as the skin,
lung, and intestine. Importantly, these
DC subsets have different functions,
offering the possibility that directed tar-
geting to these individual subsets can
induce specific vaccine responses. In
the accompanying review by Roy and
Klein (Roy and Klein, 2012), the role and
importance of the various DC subsets in
antifungal immunity are explored as well
as the recent advances in the targeting
of these cells for the development anti-
fungal vaccines. However, despite this
progress, there are still no vaccines clini-
cally available for any fungal pathogen.
Adaptive Immunity: Th17 and
Antibody Responses
While the innate effector functions of
phagocytes, particularly those of neutro-
phils and macrophages, are sufficient for
protection against some infections,
defense against most fungal pathogens
also requires adaptive immune re-
sponses. As already mentioned, adaptive
immunity is induced and modulated
following interactions of microbes with
phagocyte PRRs and the subsequent
cytokine and chemokine profiles that are
produced. In fact, interactions of fungi
with particular PRRs have been directly
linked to the induction of specific types
of adaptive responses, including Th1
(TLR4, for example) and Th2 (TLR2, for
example) immunity (Netea et al., 2008;
Wu¨thrich et al., 2012). More recently,
fungal recognition by CLRs and NLRs11, May 17, 2012 ª2012 Elsevier Inc. 423
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(see below). Understanding the role of
PRRs in driving these responses has had
significant implications for our under-
standing of the mechanisms underlying
the induction of protective antifungal
adaptive immunity and the possibility of
modulating immunity for vaccine design,
topics that are discussed further in the
associated reviews by Herna´ndez-Santos
and Gaffen (Herna´ndez-Santos and Gaf-
fen, 2012) and by Roy and Klein (Roy
and Klein, 2012) in this issue.
Historically, inflammatorycytokinesand
Th1 responses were considered to
provide protection against fungal infec-
tions, while immunosuppressive cyto-
kines and Th2 responses were thought to
contribute to susceptibility. This concept
was supported by both human patients
and animal models in which deficiencies
in Th1 or inflammatory cytokines (such as
IFN-g or TNF, for example), or upregula-
tion of Th2 or immunosuppressive cyto-
kines (IL-4 and IL-10, for example) led to
enhanced susceptibility to infections with
various fungal pathogens (Romani, 2011).
However, this distinction was not always
clear-cut; for example, nonprotective
cytokines, such as IL-10, are required to
limit inflammatory pathology, in part by
promoting the development of Tregs cells,
whereas some level of IL-4 is needed to
induce protective immunity. Furthermore,
deficiencies in Th1 responses did not al-
ways correlate to susceptibility, especially
for mucocutaneous fungal infections.
This latter paradox was solved recently
following the identification of Th17 adap-
tive immunity, responseswhichwere orig-
inally linked to autoimmunity. Interest-
ingly, Th17 responses (characterized by
the production of IL-17 and several other
cytokines, including IL-22 and IL-23)
appear to be primarily responsible for
protection against fungal infections at
the mucosa. The mechanisms for this
protection are still being elucidated, but
are thought to involve neutrophil recruit-
ment and antimicrobial peptide produc-
tion at the site of infection. These re-
sponses may also be partially required
for the control of systemic infections
caused by some (but not all) fungal path-
ogens, including Candida, Aspergillus,
and Cryptococcus (Wu¨thrich et al., 2012).
While there is contradictory evidence
from certain mouse models, which
suggest that inflammation induced424 Cell Host & Microbe 11, May 17, 2012 ª2during Th17 responses can contribute to
pathologyaswell as susceptibility, defects
in Th17 immunity have been directly linked
to susceptibility to mucocutaneous fungal
infections in man. The most common
infection observed in these patients
is chronic mucocutaneous candidiasis
(CMC), and several other diseases previ-
ously associated with CMC, such as
hyperimmunogolublin E syndrome and
autoimmune polyendocrine syndrome 1,
have now been linked to alterations
in Th17 respones. A detailed account
of Th17 responses in immunity to
Candida albicans is presented in the
review by Herna´ndez-Santos and Gaffen
(Herna´ndez-Santos and Gaffen, 2012) in
this issue of Cell Host & Microbe.
While it is clear that cell-mediated
immunity is essential for resistance to
fungal infections, humoral immunity has
longbeen considered to have a secondary
role. Indeed, studies looking at the
passive transfer of immune sera or using
B cell-deficient mice, for example, have
failed to reliably demonstrate the impor-
tance of antibodies in antifungal immu-
nity. However, the development and char-
acterization of monoclonal antibodies
(mAbs) has provided clear evidence that
antibodies can mediate both protection
and susceptibility (Casadevall and Pirof-
ski, 2012b). Such opposing functions
presumably counteract each other during
the polyclonal responses initiated during
fungal infections, explaining the earlier
findings. Excitingly, however, protective
mAbs could be used for the development
of novel therapeutics, and protective anti-
body responses generated following the
targeting of specific fungal antigens offers
the potential for vaccine development.
Indeed, antibodies to common antigens,
such as b-glucans, could provide cross-
species protection. The latest develop-
ments in this area are covered in detail in
the review by Casadevall and Pirofski
(Casadevall and Pirofski, 2012a) in this
issue of Cell Host & Microbe.
Conclusions
The last few years have seen substantial
advances in our understanding of anti-
fungal immunity. Although a previously
‘‘neglected’’ area, these developments
have promoted renewed interest in fungal
infections and a rapid expansion of the
field. Despite the important discoveries
and successes of the last years, many of012 Elsevier Inc.which were not discussed here, consider-
able challenges still remain. Developing
vaccines that will be effective in immuno-
compromised patients is just one ex-
ample. Furthermore, most attention has
been focused on understanding the
immunopathological mechanisms of the
major invasive fungal pathogens that
occur in immunocompromised patients
in the developed societies, yet we still
know little about the terrible endemic
mycoses that affect thousands of individ-
uals in the developing world or the com-
mon mucocutaneous infections that
affect millions worldwide. No doubt ex-
citing developments in these areas will
be forthcoming in the future.
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